trastuzumab + bevacizumab + paclitaxel

This is a combination regimen consisting of three drugs—trastuzumab, bevacizumab, and paclitaxel—used primarily in the treatment of HER2-positive breast cancer. Trastuzumab is a humanized monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting proliferation and survival of HER2-overexpressing tumor cells[3]. Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis required for tumor growth[1][6]. Paclitaxel is a small molecule chemotherapeutic agent that stabilizes microtubules, preventing cell division and inducing apoptosis. The combination aims to target both tumor cell proliferation (via HER2 inhibition) and tumor vasculature (via VEGF inhibition), while also providing cytotoxic chemotherapy with paclitaxel. This regimen has been investigated in phase II clinical trials for locally advanced or metastatic HER2-positive breast cancer, showing feasibility but with notable toxicity concerns related to bevacizumab[1][6].

Other names

trastuzumab, bevacizumab with paclitaxel (triple combination)